IDXX:NASDAQIDEXX Laboratories, Inc. Analysis

IDEXX posted a strong Q1 with ~14% revenue growth and expanding margins, lifting its 2026 outlook and reinforcing its position in the fast‑growing companion‑animal and water‑testing markets. Operating margin rose to 31.8% and ROE sits at an eye‑popping 73%, underscoring the company’s profitability engine. However, the stock trades at a PE of 41, well above the diagnostics industry average of 27.6, and a price‑to‑book of 27.8, suggesting a significant valuation premium. Technicals show the price (≈$559) sitting just below the near‑term resistance of $585 and above the 20‑day SMA, while the MACD histogram turned positive and the MACD signal is bullish, hinting at short‑term momentum despite a broader bearish trend. Volatility remains high at 31% over the past 30 days and beta exceeds 1.3, indicating sensitivity to market swings. The DCF fair‑value estimate of roughly $224 is far below current levels, pointing to a sizable downside risk if expectations are re‑aligned.